Treace Medical Concepts (TMCI) Q4 Loss Narrowing To US$0.15 EPS Tests Bearish Narratives

Treace Medical Concepts (TMCI) just posted its FY 2025 fourth quarter numbers with revenue of US$62.5 million and a basic EPS loss of US$0.15, while the trailing 12 month figures show revenue of US$212.7 million and a basic EPS loss of US$0.93, set against roughly 4% revenue growth on a trailing basis. Over recent quarters, the company has seen revenue move from US$45.1 million in Q3 2024 to US$52.6 million in Q1 2025, US$47.4 million in Q2 2025, US$50.2 million in Q3 2025 and US$62.5 million in Q4 2025. Basic EPS losses ranged between US$0.25 and US$0.28 over the first three quarters of 2025 before narrowing to US$0.15 in Q4, which keeps the focus firmly on how quickly margins can tighten toward a more sustainable level.

See our full analysis for Treace Medical Concepts.

With the latest figures on the table, the next step is to see how these margins and growth trends line up with the most widely held narratives around Treace Medical Concepts and where those stories may need updating.

See what the community is saying about Treace Medical Concepts

US$59 million loss over the year keeps profitability in focus

• On a trailing 12 month basis, Treace Medical Concepts recorded revenue of US$212.7 million and a net loss of US$59.0 million, with basic EPS at a loss of US$0.93.
• Consensus narrative points to long term revenue expansion and eventual margin improvement, yet the current loss profile tests that view
  • Analysts looking for profit margin to move toward the US medical equipment industry average must reconcile this with trailing net losses ranging from US$49.2 million to US$61.5 million over recent 12 month periods.
  • With revenue growth of about 4% per year, which is below the broader US market’s 11.4%, the idea of sustained earnings expansion relies on margin improvement rather than top line acceleration alone.

Quarterly losses narrow from US$17.4 million to US$9.4 million

• Within FY 2025, net loss moved from US$17.4 million in Q2 and US$16.3 million in Q3 to US$9.4 million in Q4, alongside basic EPS losses tightening from US$0.28 in Q2 to US$0.15 in Q4.
• Bulls argue that stronger adoption and operating efficiency can drive faster earnings progress, and the recent quarterly pattern gives them specific data to point to
  • The bullish view leans on expanding clinical usage and an experienced sales force to support revenue, which lines up with quarterly revenue between US$47.4 million and US$62.5 million across FY 2025 while per share losses narrowed into year end.
  • At the same time, the stock trades at a P/S of 0.6x versus peer and industry averages of 1.7x and 2.8x. Any sustained improvement in losses from the Q2 and Q3 levels could heavily support the bullish case that the current multiple does not fully reflect future earnings potential.

On a quarter where losses narrowed and revenue stayed above US$47 million, some investors will want to see how bullish arguments about faster margin improvement stack up against the detailed projections in the full narrative. 🐂 Treace Medical Concepts Bull Case

Low 0.6x P/S contrasts with five year loss deterioration

• Treace Medical Concepts trades on a trailing 12 month P/S of 0.6x while losses have grown at an annualized 27.2% over the past five years, and the company remains unprofitable with forecasts indicating continued losses.
• Bears highlight that ongoing losses and recent volatility may outweigh the appeal of the low multiple
  • The bearish narrative focuses on pressures from elective procedure deferrals and product mix, which aligns with trailing 12 month losses between US$50.1 million and US$61.5 million even as revenue hovered around US$202.9 million to US$218.9 million.
  • With revenue growth at about 4% per year and the share price recently at US$1.92, the gap between the current valuation and the US medical equipment industry’s higher averages keeps the question front and center of whether the discount reflects these persistent losses and recent share price volatility.

If you are weighing the 0.6x P/S against five years of widening losses, it can help to see how skeptics frame that trade off in detail through the full bearish narrative. 🐻 Treace Medical Concepts Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Treace Medical Concepts on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both optimism and concern in these numbers, it makes sense to review the details yourself and move quickly to your own view. To round out that picture, take a look at the 1 key reward and 2 important warning signs

See What Else Is Out There

Treace Medical Concepts carries a trailing net loss of US$59.0 million, widening losses over five years and revenue growth of about 4% per year.

If this mix of ongoing losses and modest growth leaves you wanting a sturdier profile, compare it with companies in the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com